THX Pharma: a strategic evolution towards international expansion

Pharmaceutical company Theranexus, now revived as THX Pharma, is strengthening its growth strategy by focusing on the registration and international commercialization of its rare disease drugs. With its TX01 and Batten-1 candidates, the company aims to achieve a global commercial presence by 2028, marking a transition from a pure-play biotechnology entity to a pharmaceutical industrial player.

THX Pharma anticipates significant revenues, targeting €50 million annually for TX01 by 2031-2032 through partnerships with Exeltis in Europe and future ventures in the United States, Canada, and Australia. For Batten-1, development is moving toward a lean plan thanks to promising efficacy data, targeting €200 million in additional revenues by 2032-2033.

With these initiatives, and the support of Bpifrance for its antisense oligonucleotide platform, THX Pharma aims to position itself as a leader in the sector of drugs for rare diseases.